Pei Shi Ong - Search Results

Year	Number of Results
2003	1
2011	2
2012	6
2013	2
2014	1
2016	4
2017	1
2018	4
2019	2
2021	2
2024	0

1

Resveratrol for cancer therapy: Challenges and future perspectives.

Ren B, Kwah MX, Liu C, Ma Z, Shanmugam MK, Ding L, Xiang X, Ho PC, Wang L, Ong PS, Goh BC. Ren B, et al. Among authors: ong ps. Cancer Lett. 2021 Sep 1;515:63-72. doi: 10.1016/j.canlet.2021.05.001. Epub 2021 May 28. Cancer Lett. 2021. PMID: 34052324 Free article. Review.

2

A Review on Liquid Chromatography-Tandem Mass Spectrometry Methods for Rapid Quantification of Oncology Drugs.

Wong AL, Xiang X, Ong PS, Mitchell EQY, Syn N, Wee I, Kumar AP, Yong WP, Sethi G, Goh BC, Ho PC, Wang L. Wong AL, et al. Among authors: ong ps. Pharmaceutics. 2018 Nov 8;10(4):221. doi: 10.3390/pharmaceutics10040221. Pharmaceutics. 2018. PMID: 30413076 Free PMC article. Review.

3

Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its development.

Wang L, Phan DD, Zhang J, Ong PS, Thuya WL, Soo R, Wong AL, Yong WP, Lee SC, Ho PC, Sethi G, Goh BC. Wang L, et al. Among authors: ong ps. Oncotarget. 2016 Jul 12;7(28):44790-44802. doi: 10.18632/oncotarget.8316. Oncotarget. 2016. PMID: 27027349 Free PMC article. Review.

4

Clinical therapeutics for phenylketonuria.

Kochhar JS, Chan SY, Ong PS, Kang L. Kochhar JS, et al. Among authors: ong ps. Drug Deliv Transl Res. 2012 Aug;2(4):223-37. doi: 10.1007/s13346-012-0067-1. Drug Deliv Transl Res. 2012. PMID: 25787029

5

Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives.

Ong PS, Wang LZ, Dai X, Tseng SH, Loo SJ, Sethi G. Ong PS, et al. Front Pharmacol. 2016 Oct 25;7:395. doi: 10.3389/fphar.2016.00395. eCollection 2016. Front Pharmacol. 2016. PMID: 27826244 Free PMC article. Review.

6

Celastrol in cancer therapy: Recent developments, challenges and prospects.

Lim HY, Ong PS, Wang L, Goel A, Ding L, Li-Ann Wong A, Ho PC, Sethi G, Xiang X, Goh BC. Lim HY, et al. Among authors: ong ps. Cancer Lett. 2021 Sep 8;521:252-267. doi: 10.1016/j.canlet.2021.08.030. Online ahead of print. Cancer Lett. 2021. PMID: 34508794

7

Current trends in modern pharmaceutical analysis for drug discovery.

Koh HL, Yau WP, Ong PS, Hegde A. Koh HL, et al. Among authors: ong ps. Drug Discov Today. 2003 Oct 1;8(19):889-97. doi: 10.1016/s1359-6446(03)02846-0. Drug Discov Today. 2003. PMID: 14554017 Review.

8

Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling.

Wang L, Syn NL, Subhash VV, Any Y, Thuya WL, Cheow ESH, Kong L, Yu F, Peethala PC, Wong AL, Laljibhai HJ, Chinnathambi A, Ong PS, Ho PC, Sethi G, Yong WP, Goh BC. Wang L, et al. Among authors: ong ps. Cancer Lett. 2018 Mar 28;417:152-160. doi: 10.1016/j.canlet.2017.12.030. Epub 2018 Jan 4. Cancer Lett. 2018. PMID: 29306016

9

Quantification of desoxyrhapontigenin (4-methoxyresveratrol) in rat plasma by LC-MS/MS: Application to pre-clinical pharmacokinetic study.

Dai Y, Tan ALC, Chen H, Ong PS, Xiang X, Wu J, Lin HS. Dai Y, et al. Among authors: ong ps. J Pharm Biomed Anal. 2018 May 10;153:95-101. doi: 10.1016/j.jpba.2018.02.026. Epub 2018 Feb 13. J Pharm Biomed Anal. 2018. PMID: 29471224

10

A miniaturized flow-through cell to evaluate skin permeation of endoxifen.

Mah CS, Kochhar JS, Ong PS, Kang L. Mah CS, et al. Among authors: ong ps. Int J Pharm. 2013 Jan 30;441(1-2):433-40. doi: 10.1016/j.ijpharm.2012.11.011. Epub 2012 Nov 19. Int J Pharm. 2013. PMID: 23174412

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

21 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year